Larry Wang and the art of starting twice

Larry Wang’s latest company chapter begins with someone else getting the same title. In January 2026, Vibrant Therapeutics named Han Lee co-CEO alongside its founder. Wang also remains CTO. A person who had already helped establish one company was now making room at the top of another. The announcement contained a financing figure, as announcements tend to do. The more interesting detail was the extra name.

Business profiles have a weakness for solitary founders. One person has an idea, assembles a team, acquires a tasteful photograph and proceeds through a succession of increasingly large numbers. Wang’s career offers a more crowded picture. There are colleagues at the beginning, colleagues from earlier employers, and a new executive partner in the present. The people deserve to stay in the frame.

His first founding chapter was GenScript, established in 2002 with Frank Zhang and Sally Wang. His second was Vibrant, founded in 2019. Seventeen years separate the two beginnings. Those years include the less theatrical work of running an organization, taking responsibility for systems and remaining involved as the company changes around its founders.

Before the title, the code

Wang’s formal education began with biochemistry. He completed his undergraduate degree at Shandong University in 1991, then pursued doctoral research at Rutgers in New Jersey. His PhD followed in 1996. The academic route crossed countries and disciplines, but a smaller change inside that route helps explain the technical work that came later.

During his doctorate, he began using code to analyze biological data. He described that shift in a 2021 interview, recalling an earlier identity as a molecular biologist. Programming entered through a task that needed solving. It was useful work before it became part of an executive biography.

There is something pleasantly unceremonious about that origin. A computer does not require a five-year career plan before it will run a program. It does, however, insist on instructions. The practical attraction is easy to understand: once a question can be expressed clearly enough, a repetitive piece of analysis can become a procedure.

The distinction matters when reading Wang’s later titles. Bioinformatics puts computational methods alongside biological questions. It asks the person building a system to understand both the information and the reason someone wants to use it. In his career, the computational role grew out of an existing research practice.

Rutgers was followed by Schering-Plough Research Institute, where he worked as a senior principal scientist. That move placed him inside industrial research. The environment changed; analysis remained part of the job. Eventually another responsibility arrived: helping create the organization in which the work would happen.

Three names at the beginning

GenScript’s founding team included Zhang, Wang and Sally Wang. Keeping all three names visible gives the story its proper proportions. Wang’s role belongs within that partnership. Entrepreneurship already had a plural form before his current co-CEO arrangement made the point explicit in an organization chart.

The early business supplied research services and materials. By 2009, it had attracted a $15 million investment led by Kleiner Perkins Caufield & Byers’ China fund. Its operations then extended across the United States, China, France and Japan. This was an organization selling work to other organizations, with the coordination that such a business requires.

A service business gives technical competence a very practical examination. Another team needs the result, needs to understand what it is receiving, and needs it to arrive in a usable form. The company must organize that exchange repeatedly. A clever method can help win an order; an operating organization must fulfill it.

Wang served as president of GS Corp from 2003 to 2014. Eleven years is a substantial stretch of a working life. It also changes the scale at which a founder is useful. The job reaches beyond the initial technical contribution into decisions about how the business continues to function.

His public appearances during those years placed him among other working executives. In 2009, he was listed on a BioPacific conference panel about biotechnology and entrepreneurship. In 2011, the PKU Bio-Net reunion in New York included him among its guests. These are small entries in the chronology, but they locate the company president in a wider professional community.

The conference program is a modest corrective to the lone-founder photograph. It puts several names on the same line of discussion. Companies develop amid other companies, researchers, advisers and investors. Wang’s early executive chapter took place in that shared setting.

There is another technical role behind the executive history. Vibrant describes Wang as GenScript’s chief bioinformatics system architect. An architect’s contribution sits in the arrangement of a system: how its pieces relate, what information moves between them, and how people can use the result. It gives the career a connecting thread between the early programmer and the later company leader. Designing the machinery of work and organizing the people doing it are different responsibilities, but his biography contains both.

The chapters overlap

A career timeline can make every move look like a clean departure. Wang’s chronology is less obliging. His executive work at GenScript was followed by non-executive board service, and that relationship continued after Vibrant had been founded. The second beginning did not instantly erase the first.

In May 2015, he was appointed a GenScript director; in August, his position became non-executive. In December 2020, he became CEO and chairman of Vibrant Pharma Ltd. He left GenScript’s non-executive board on May 29, 2025. The sequence shows different responsibilities existing alongside one another before the older board chapter closed.

That overlap is useful to remember. A new venture can have a founding date while its founder still carries obligations elsewhere. The calendar records appointments more neatly than a working week can contain them. Reading the roles in sequence gives us a clearer picture than assuming that each new line replaced everything above it.

Starting again also poses a question about what experience can do. It can supply familiarity with hiring, operations and the language of investors. It cannot make a new organization identical to the old one. Different colleagues and a different project still require decisions of their own.

Wang’s present combination of co-CEO and CTO makes that question concrete. The technical title remains beside the organizational one. His current job therefore keeps the company’s computational work close to its leadership, while the shared CEO title adds another person to the responsibility for its direction.

“We are pleased to close these financings and welcome Dr. Lee as co-CEO”

Larry Wang, January 2026

A company built across two places

Vibrant’s footprint includes Guangzhou and Cambridge, Massachusetts. Its team includes people whose earlier careers passed through Schering-Plough, Merck and GenScript. The new company brings together previous experience without simply reproducing a single previous employer.

Lili Huang is its operations leader and a co-founder. Han Lee’s earlier roles include finance and company leadership at Arcellx, Neogene and ImmPACT Bio. Wang’s own work connects scientific analysis, technical systems and executive responsibility. The names and functions make the organization easier to understand than a collection of adjectives would.

The January 2026 announcement paired Lee’s arrival with $61 million in new financing. Goodwin, which advised on the transaction, reported that total capital raised had reached $100 million. The funding plans included expanding the team and supporting global development. For this stage of Wang’s career, the financing belongs beside the leadership change.

The financing brought new investors Pfizer Ventures and Apricot Capital together with Bayland Capital, HSG, Northern Light Venture Capital and First Principle Venture Limited. The list extends the cast of the second founding chapter. A company’s next stage involves more people with a stake in its decisions, as well as more people carrying out its work.

Money gives an organization room to act. It also gives its leaders more choices to make. Which colleagues should join? Which work needs support? What should be organized differently as the team expands? These are ordinary company-building questions, even when the number attached to them has eight digits.

The shared CEO office is one answer visible in the announcement. It places Wang and Lee together at the top while Wang retains the technical role. We can describe that arrangement precisely without imagining their private division of labor or turning the appointment into a claim about either person’s temperament.

By June 2026, the BIO International Convention’s company listing named both men as CEOs and identified Leon Wert-Lamas as the primary speaker for Vibrant’s presentation. The public-facing work had another colleague attached to it. The organization was again larger than its founder’s photograph.

Wang’s career now contains two founding chapters and several ways of contributing between them. The doctoral student used programming to get analysis done. The scientist worked within an established research institution. The company president helped operate a business. The founder returned to building, and the current executive shares the top title.

There is no need to give that sequence a miraculous ending. Its interest lies in the changing work. A founder can remain technically involved, carry experience forward and add colleagues whose backgrounds bring something different to the table. Larry Wang’s next chapter has begun with exactly that sort of addition: another name beside his own.